Egetis Therapeutics AB (publ) (EGTX) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Egetis Therapeutics Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.955 Welcome to AGEDIS Therapeutics Q2 Report 2026. 00:00:03.955 -- 00:00:08.640 For the first part of the conference call, the participants will be in listen-only mode. 00:00:08.640 -- 00:00:13.786 During the questions and answers session, participants are able to ask questions by dialing 00:00:13.786 -- 00:00:19.052 pound key five on their telephone keypad. Now I will hand the conference over to CEO 00:00:19.052 -- 00:00:22.694 Nicholas Westerholm. Please go ahead. 00:00:22.795 -- 00:00:28.263 Thank you, EVOperator. Good afternoon, good morning and a warm welcome to Aegitis Therapeutics 00:00:28.263 -- 00:00:32.589 Quarter 2 Results webcast, planned for the coming 30 minutes. 00:00:32.589 -- 00:00:36.635 For those who I haven't had the privilege to meet before, my name is Niklas Westerholm 00:00:36.635 -- 00:00:39.730 and I am the CEO of the company. 00:00:39.730 -- 00:00:42.772 I will start today's session with a short business update. 00:00:42.772 -- 00:00:48.354 This will be followed by Annie Bedard, President of our US and North American business, 00:00:48.354 -- 00:00:53.697 who will discuss the launch preparations for the planned MC-Tate launch in the US, subject 00:00:53.697 -- 00:00:55.498 to approval. 00:00:55.498 -- 00:01:00.540 Then Henrik Krook, Vice President Commercial Operations, will give a commercialization 00:01:00.540 -- 00:01:06.460 update of MC-Tate in the European Union, as well as other international markets. 00:01:06.460 -- 00:01:11.928 Finally, Yilmaz Masheed, Chief Financial Officer, will provide a financial update 00:01:11.928 -- 00:01:17.655 before we're looking ahead to the exciting upcoming key value enhancing milestones. 00:01:17.655 -- 00:01:23.420 We're aimed to leave ample time for Q&A at the end of t...